四种常见肿瘤标记物联合检测在肝胆系统良恶性疾病中的临床价值

表1 肿瘤标志物在肝胆良恶性疾病诊断中的比较分析 (mean±SD)

分组	n	AFP(ng/mL)	CEA(ng/mL)	CA19-9(U/mL)	CA125(U/mL)
健康正常对照组	40	8.17±2.85	2.42±0.35	9.44±2.79	9.08±1.79
肝脏良性疾病组	112	10.63±4.261	2.62±0.691	11.26±3.841	9.27±2.051
肝脏恶性疾病组	75	358.03±103.172	68.95±15.292	82.62±17.942	73.73±14.582
胆道良性疾病组	67	7.93±2.163	2.05±0.743	10.52±2.533	9.42±2.063
胆道恶性疾病组	16	118.67±33.864	52.88±8.844	302.58±45.024	81.18±15.874

¹肝脏良性组与健康组比较: AFP: t = 1.96, P = 0.23; CEA: t = 2.08, P = 0.27; CA19-9: t = 1.99, P = 0.24; CA125: t = 0.72, P = 0.69;

²肝脏良性组与恶性组比较: AFP: t = 43.65, P = 0.00; CEA: t = 45.90, P = 0.00; CA19-9: t = 40.77, P = 0.00; CA125: t = 46.17, P = 0.00;

³胆道良性组与健康组比较: AFP: t = 0.78, P = 0.48; CEA: t = 0.88, P = 0.45; CA19-9: t = 1.77, P = 0.09; CA125: t = 0.71, P = 0.55;

⁴胆道良性组与恶性组比较: AFP: t = 26.03, P = 0.00; CEA: t = 44.81, P = 0.00; CA19-9: t = 50.01, P = 0.00; CA125: t = 33.76, P = 0.00; AFP: 甲胎蛋白; CEA: 癌胚抗原; CA19-9: 糖链抗原19-9; CA125: 糖链抗原125.